Clinical Trials & Research Studies in Canada(Updated 8/25)

MDMA-Assisted CBCT for PTSD vs CBCT RCT

NCT06044675

Recruiting

This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery. CBCT is a manu... Read More

This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery. CBCT is a manualized treatment for PTSD that simultaneously addresses PTSD symptoms and relationship satisfaction. It provides dyads with behavioral tools to navigate PTSD-related challenges, as well as the knowledge behind PTSD and how it impacts relationships. Previous research has demonstrated the efficacy of CBCT in improving PTSD symptoms, partner functioning, and relationship satisfaction in both distressed and non-distressed dyads. MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CBCT due to its ability to induce empathy and interpersonal openness. This randomized study is the second study designed to explore the efficacy of combining MDMA-assisted therapy with CBCT. This study will enroll 30 dyads, where one individual has symptoms of PTSD. Participants will undergo a 7-week psychotherapy course, in MDMA-assisted CBCT or CBCT alone. In the MDMA-assisted CBCT, participants will go through CBCT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Participants assigned to the CBCT-only condition will go through CBCT sessions and will have the opportunity to crossover and receive the two MDMA sessions after follow-up. The primary goal of this research is to contribute to the literature on MDMA-assisted CBCT by investigating its feasibility, safety, acceptability, and effectiveness, and by comparing it to active PTSD treatments. Read Less

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

11/22/2024

Locations: Remedy Institute, Toronto, Ontario

Conditions: Post Traumatic Stress Disorder

Register for Updates

Learn More ›

Timing of TAP Blocks in Bariatric Surgery

NCT06270147

Recruiting

This clinical trial aims to determine the optimal timing for administering a Transversus Abdominis Plane (TAP) block in bariatric surgery, specifically investigating whether initiating TAP blocks at the beginning of surgery is more beneficial than at the end, which is the current practice. The study targets obese patients undergoing bariatric surgery, with a focus on reducing postoperative pain and opioid use. Key outcomes include recovery duration, pain levels, opioid consumption, and respirato... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/22/2024

Locations: St. Joseph's Healthcare Hamilton - Charlton Campus, Hamilton, Ontario

Conditions: Opioid Use, Pain, Postoperative

Register for Updates

Learn More ›

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

NCT06704321

Recruiting

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

11/22/2024

Locations: Institut sur la nutrition et les aliments fonctionnels (INAF), Québec, Quebec

Conditions: Non-Alcoholic Fatty Liver Disease

Register for Updates

Learn More ›

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

NCT03151629

Recruiting

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance. Read Less

Gender:

MALE

Ages:

21 years and above

Trial Updated:

11/21/2024

Locations: University of Alabama-Birmingham, Birmingham, Alabama +120 locations

University of Alabama-Birmingham, Birmingham, Alabama

University of Alabama- Tuscaloosa, Tuscaloosa, Alabama

University of California - Los Angeles, Los Angeles, California

University of California San Diego, San Diego, California

Yale University, New Haven, Connecticut

University of Florida, Gainesville, Florida

Mayo Clinic Jacksonville, Jacksonville, Florida

Moffitt Cancer Center, Tampa, Florida

Morehouse School of Medicine, Atlanta, Georgia

Emory Winship Cancer Institute, Atlanta, Georgia

University of Illinois at Chicago, Chicago, Illinois

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Kishwaukee Cancer Center, DeKalb, Illinois

Delnor Cancer Center, Geneva, Illinois

Warrenville Cancer Center, Warrenville, Illinois

Tulane University, New Orleans, Louisiana

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Chesapeake Urology Associates, Towson, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts

University of Michigan, Ann Arbor, Michigan

Karmanos Cancer Institute, Detroit, Michigan

University of Mississippi Medical Center, Jackson, Mississippi

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

VA Western New York Healthcare System, Buffalo, New York

Columbia University Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Weill Cornell Medical Center, New York, New York

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Durham VA Medical Center, Durham, North Carolina

Duke Cancer Network, Durham, North Carolina

Duke University, Durham, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Oregon Health & Science University Hospital, Portland, Oregon

Doylestown Health, Doylestown, Pennsylvania

Thomas Jefferson University, Philadelphia, Pennsylvania

Fox Chase Cancer Center - Temple Health, Philadelphia, Pennsylvania

Reading Health System, West Reading, Pennsylvania

Ralph H. Johnson VA Medical Center, Charleston, South Carolina

William Jennings Bryan Dorn VAMC, Columbia, South Carolina

Memphis VA Medical Center, Memphis, Tennessee

Baptist Clinical Research Institute, Memphis, Tennessee

Baylor College of Medicine, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington Medical Center, Seattle, Washington

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Royal Brisbane & Women's Hospital, Herston, Brisbane

St. Vincent's Hospital Sydney, Darlinghurst, New South Wales

Macquarie University, Sydney, New South Wales

Westmead Hospital, Sydney, New South Wales

Redland Hospital, Cleveland, Queensland

Princess Alexandra Hospital, Woolloongabba, Queensland

Eastern Health (Box Hill Hospital), Box Hill, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria

Epworth Healthcare, Mount Waverley, Victoria

Australian Prostate Centre, Melbourne N., Not set

Australian Urology Associates, Melbourne, Not set

The University of the West Indies - Cave Hill Campus, Bridgetown, Not set

Tacchini Hospital, Bento Gonçalves, Rio Grande Do Sul

Hospital Beneficência Portuguesa, Bela Vista, São Paulo

Instituto do Câncer e Transplante, Curitiba, Not set

Centro de Pesquisa em Oncologia, Porto Alegre, Not set

Centro Paulista de Oncologia, São Paulo, Not set

Instituto Câncer do Estado de São Paulo, São Paulo, Not set

Cross Cancer Institute (Alberta Health Services), Edmonton, Alberta

BC Cancer Agency, Vancouver, British Columbia

Juravinski Cancer Centre, Hamilton, Ontario

Ottawa Hospital Cancer Centre, Ottawa, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec

CHU de Québec-Université Laval, Québec, Quebec

Beacon Hospital, Dublin, Leinster

Tallaght University Hospital, Dublin, Not set

St. Vincent's University Hospital, Dublin, Not set

Sligo University Hospital, Sligo, Not set

The University of the West Indies - Mona Campus, Kingston, Not set

University of Nairobi, Nairobi, Not set

Federal Medical Centre Abeokuta, Abeokuta, Not set

University of Ilorin Teaching Hospital, Ilorin, Not set

Lagos State University Teaching Hospital, Lagos, Not set

University of Maiduguri Teaching Hospital, Maiduguri, Not set

Oslo University Hospital, Oslo, Not set

The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng

Steve Biko Academic Hospital, Pretoria, Gauteng

Groote Schuur Hospital, Cape Town, Not set

Vall d'Hebron Institute of Oncology, Barcelona, Catalunya

Institut Catalá d'Oncologia Badalona, Badalona, Not set

Fundació Institut Mar d'Investigacions Mèdiques (Hospital del Mar)., Barcelona, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Provincial de Castellón, Castellón De La Plana, Not set

Hospital Universitario La Princesa, Madrid, Not set

Hospital Clinico San Carlos, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Instituto Valenciano de Oncología, Valencia, Not set

Hospital Universitario Miguel Servet (Zaragoza), Zaragoza, Not set

Skane University Hospital, Malmö, Skane

Umea University Hospital, Umeå, Not set

Orebro University Hospital, Örebro, Not set

Universitätsspital Basel, Basel, Not set

Ente Ospedaliero Cantonale, Bellinzona, Not set

Kantonsspital Graubünden, Chur, Not set

Kantonsspital St. Gallen, Saint Gallen, Not set

Onkozentrum Zürich, Zürich, Not set

Universitätsspital Zürich, Zürich, Not set

University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire

Lister Hospital, Stevenage, Hertfordshire

Mount Vernon Cancer Centre, Northwood, Middlesex

Velindre Cancer Centre, Cardiff, Not set

University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, Not set

Guys St Thomas NHS Foundation Trust, London, Not set

The Royal Marsden NHS Foundation Trust, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Not set

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Not set

South Tyneside District Hospital, South Shields, Not set

Sunderland Royal Hospital, Sunderland, Not set

Clatterbridge Cancer Centre, Wirral, Not set

Conditions: Prostate Cancer

Register for Updates

Learn More ›

Online Memory Intervention for Individuals with Traumatic Brain Injury

NCT04331392

Recruiting

This study will examine the behavioural and neurophysiological efficacy and feasibility of an online spatial navigation intervention for improving memory and brain health in individuals who have sustained moderate-severe traumatic brain injury.

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

11/21/2024

Locations: Toronto Rehabilitation Institute, Toronto, Ontario

Conditions: Brain Injuries, Traumatic, Brain Injury Traumatic Severe, Brain Injury Traumatic Moderate, Brain Injury, Chronic

Register for Updates

Learn More ›

Stepped Care for Youth at Risk of Psychosis

NCT04829292

Recruiting

The study will recruit 60 young people who meet established criteria for being at clinical high risk for psychosis. They will be offered a range of psychological interventions starting with the most benign treatments in different steps. At step 1 they will be offered individual or group support and if there is no improvement they will be offered more intensive CBT individual therapy or CBSST group therapy. Assessments will occur at baseline, 6,12 and 18 months

Gender:

ALL

Ages:

Between 12 years and 30 years

Trial Updated:

11/21/2024

Locations: Mathison Centre for Research and Education, University of Calgary, Calgary, Alberta

Conditions: Clinical High Risk for Developing Psychosis

Register for Updates

Learn More ›

Neural Mechanisms of Intermittent Theta Burst Stimulation in the Core Depression Network

NCT05224206

Recruiting

Repetitive Transcranial magnetic stimulation (TMS) uses magnetic fields to modulate brain activity. A novel form of repetitive TMS (rTMS), intermittent theta burst stimulation (iTBS), has emerged as a promising new treatment for depression. This technique may be advantageous due to its very short duration and potentially stronger effect on brain activity in comparison with standard rTMS. However, the exact effect of iTBS on the activity of the brain in clinical populations remains poorly underst... Read More

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

11/21/2024

Locations: The Royal Ottawa Mental Health Centre, Ottawa, Ontario

Conditions: Major Depressive Disorder

Register for Updates

Learn More ›

Self-Management Interventions for Long COVID-19

NCT05268523

Recruiting

The purpose of this study is to investigate and compare the feasibility and efficacy of two group-based interventions (education vs. mindfulness) to help self-manage Long-COVID symptoms.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/21/2024

Locations: Toronto Rehabilitation Institute, Toronto, Ontario

Conditions: COVID-19

Register for Updates

Learn More ›

Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps

NCT06271941

Recruiting

Large (≥20mm) colorectal polyps often harbor areas of advanced neoplasia, making them immediate colorectal cancer (CRC) precursors. Such polyps have to be completely removed to prevent CRC and to avoid surgery and/or adjuvant therapy. The laterally spreading lesions (LSLs) are removed via endoscopic mucosal resection (EMR). However, recurrence is common. New techniques for LSL resection (hybrid argon plasma coagulation (h-APC) margin and base ablation) have shown a reduction in recurrence follow... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/21/2024

Locations: Centre Hospitalier de l'Université de Montréal, Montréal, Quebec

Conditions: Colorectal Cancer, Polyp of Colon

Register for Updates

Learn More ›

Theta Deep Brain Stimulation for Cognitive Enhancement in Parkinson's Disease

NCT06518824

Recruiting

Cognitive impairment is common in Parkinson's disease. A recent study demonstrated 40% of people with PD suffer from mild cognitive impairment and \> 80% of patients develop dementia after a disease duration of 20 years. Cognitive impairment significantly impairs quality of life and has limited treatment options. While the pathophysiology of cognitive symptoms in PD is multifactorial, one contributing factor is dysfunction in subthalamic-cortical loops. The subthalamic nucleus (STN) receives in... Read More

Cognitive impairment is common in Parkinson's disease. A recent study demonstrated 40% of people with PD suffer from mild cognitive impairment and \> 80% of patients develop dementia after a disease duration of 20 years. Cognitive impairment significantly impairs quality of life and has limited treatment options. While the pathophysiology of cognitive symptoms in PD is multifactorial, one contributing factor is dysfunction in subthalamic-cortical loops. The subthalamic nucleus (STN) receives input from distributed regions of the cortex, forming partially segregated parallel networks with sensorimotor regions, associative (cognitive) cortical regions, and limbic cortical regions. These subthalamic-cortical networks are thought to play a domain general role in inhibitory control, which is a fundamental mechanism underlying flexible behavior across motor, cognitive, and affective domains. Information processing in these subthalamic-cortical networks is expressed through oscillatory activity within distinct frequency bands. For example, communication between the STN and prefrontal regions involved in executive function is thought to occur through coherence in the theta (4-8 Hz) frequency band. As a result of these observations, stimulation of the STN at a theta frequency has been investigated as a method of modulating cognitive processes. Theta stimulation of the STN has been shown to enhance coherence in subthalamic-cortical networks, facilitating information processing and modulating behavior. For example, a recent study demonstrated that theta stimulation of the STN improved working memory performance in PD subjects, while no effect was seen for other frequency bands. The authors performed a post-hoc analysis and found that the effect may be mediated by connectivity between the stimulated STN region and the right dorsolateral prefrontal cortex (DLPFC). While these studies have demonstrated proof of principle, they are limited by small sample sizes and post-hoc analyses assessing the relationship between stimulation location and outcomes. Further research is needed to directly test the hypothesis that theta stimulation of the STN can improve executive control in PD patients by modulating associative STN circuitry. Read Less

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

11/21/2024

Locations: Leslie and Gordan Diamond Health Care Centre, Vancouver, British Columbia

Conditions: Parkinson Disease, Cognitive Impairment

Register for Updates

Learn More ›

Comparing the Efficacy of Accelerated Vs. Standard FMRI-guided ITBS in Treating Adolescents Depression

NCT06528938

Recruiting

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS), a type of rTMS, is a very promising new treatment for major depression in adults and adolescents. However, very few studies have assessed the efficacy of accelerated, three times a day TBS in comparison with standard once a day TBS in adolescents. The study aims to explore further evidence in hopes to conduct a large-scale, randomized, multisite, placebo-... Read More

Gender:

ALL

Ages:

Between 16 years and 19 years

Trial Updated:

11/21/2024

Locations: The Royal's Institute of Mental Health Research, Ottawa, Ontario

Conditions: Depression, Depressive Disorder, Major

Register for Updates

Learn More ›

AIRE-2 Device for Study of Breath Analysis in IBD

NCT06541938

Recruiting

The goal of this Prospective single-blinded intervention feasibility study is the utilization of the AIRE-2 device and FoodMarble app to elucidate the interplay among diet, symptoms, and microbial fermentable features in IBD patients with persistent intestinal symptoms and their household controls. AIRE-2 captures exhaled hydrogen and methane and FoodMarble app records breath levels, symptoms and dietary intake. The main questions it aims to answer are: 1. To assess the feasibility of using t... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

11/21/2024

Locations: McMaster University Medical Centre, Hamilton, Ontario

Conditions: Inflammatory Bowel Diseases

Register for Updates

Learn More ›

All Clinical Trials in Canada

Match to Clinical Trials